Clinical Investigation
Value of FDG PET/CT in the differential diagnosis of benign and malignant hilar mediastinal lymph nodes in patients with non-small cell lung cancer
Zhang Yuyi, Yao Zhiming, Xue Qianqian, Chen Congxia, Li Xu, Liu Xiuqin
Published 2020-09-25
Cite as Chin J Nucl Med Mol Imaging, 2020, 40(9): 513-517. DOI: 10.3760/cma.j.cn321828-20190828-00183
Abstract
ObjectiveTo investigate the diagnostic value of 18F-fluorodeoxyglucose (FDG) PET/CT in detecting N1 or N2 metastasis of lymph node (LN) with different densities in patients with non-small cell lung cancer (NSCLC).
MethodsA total of 118 patients (68 males, 50 females, age range: 27-87 (65.4±10.8) years) with N0-N2 M0 NSCLC in Beijing Hospital between October 2007 and December 2017 were included in this study. All patients underwent 18F-FDG PET/CT, followed by surgery within 1 month. The pathological findings of the resected hilar mediastinal LN were taken as the gold standard, and ratios of LN metastasis were calculated for different density groups (calcification, partial calcification, hyper density, hypodensity/isodensity). The cut-off values of LN size (short diameter) and the maximum standardized uptake value (SUVmax) in the detection of N1 and N2 metastases was determined by the receiver operating characteristic (ROC) curve, and the diagnostic efficiencies were calculated. Independent-sample t test, Mann-Whitney U test and χ2 test (partition of χ2) were used for data analysis.
ResultsA total of 433 LN has the histopathologic results: 365 LN was in stage N0, 68 LN was in stage N1-N2. There were no metastases in calcification group (0/8). The metastatic LN proportions in partial calcification group (28.6%, 8/28), hypodensity/isodensity group (20.3%, 44/217) were significantly higher than that in the hyper density group (8.9%, 16/180; χ2 values: 7.369, 9.945, both P<0.017 (threshold for partition ofχ2)). There was no significant difference between the partial group and hypodensity/isodensity group (χ2=1.021, P>0.017). The SUVmax of N1+ N2 group was significantly higher than that in N0 group (6.94 (4.51, 11.36) vs 2.45 (1.93, 3.42); z=-10.388, P<0.01). According to the ROC curve, the cut-off value of SUVmax in detecting hilar and mediastinal LN was 3.66. The diagnostic sensitivity, specificity and accuracy for N1+ N2 metastasis was 85.3%, 78.9%, 80.0% respectively. The cut-off values of SUVmax for hypodensity/isodensity group and hyper density group were 3.66 and 2.79 respectively, and the corresponding sensitivities, specificities, accuracies and positive predictive values (PPV) were 93.2%, 86.7%, 88.0%, 64.1% vs 93.8%, 57.9% (χ2=10.724), 61.1% (χ2=7.326, P<0.01), 17.9%(χ2=32.971, P<0.01). The specificity of LN size (1.0 cm)+ SUVmax was significantly higher that of LN size or SUVmax alone (94.2% vs 80.9%, 86.7%; χ2 values: 14.048, 5.661, both P<0.05) in hypodensity/isodensity group. The specificity and accuracy of LN size (1.0 cm)+ SUVmax were significantly higher those of SUVmax alone (χ2 values: 58.043, 37.037, both P<0.01) in hyper density group.
Conclusions18F-FDG PET/CT is useful in diagnosing the N1+ N2 metastases in hypodensity/isodensity LN, but has limitation in diagnosing the partial calcification LN. Combination of lymph node short diameter and SUVmax cut-off value can improve the diagnostic specificity or accuracy of 18F-FDG PET/CT for hypodensity/isodensity and high density LN.
Key words:
Carcinoma, non-small-cell lung; Lymph nodes; Positron-emission tomography; Tomography, X-ray computed; Diagnosis, differential
Contributor Information
Zhang Yuyi
Department of Nuclear Medicine, Beijing Jishuitan Hospital, Beijing 100035, China
Yao Zhiming
Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
Xue Qianqian
Department of Nuclear Medicine, the First Affiliated Hospital of Fujian Medicine University, Fuzhou 350005, China
Chen Congxia
Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
Li Xu
Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
Liu Xiuqin
Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing 100730, China